However, since different autoimmune diseases show variability in their pathophysiological processes leading to different biological markers and clinical manifestations in each disease, it would be credible to assume that low dose IL2 may not entirely have the same effect on the improvement of biological markers and clinical disease activity in different autoimmune disorders. This evidence concerns the gene IL2 and autoimmune disease.